Results 131 to 140 of about 43,704 (225)

Construction of a predictive model based on the risk of relapse after cytarabine consolidation therapy in acute myeloid leukemia patients. [PDF]

Oncologist
Ji M, Hao Y, Li W, Zhou Y, Jia R, Li W, Jin S, Dai M, Chang M, Feng L, Liu T, Zhang D, Ji C, Ye J.   +13 more
europepmc   +1 more source

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Hematological malignancies remain one of the leading causes of morbidity and mortality despite advances in targeted therapies, immunotherapy, and stem cell transplantation. Emerging evidence indicates that treatment efficacy and toxicity depend not only on the choice of therapy but also on its timing relative to the patient's internal ...
Andrej Belančić, Marko Skelin, Yun Wah Lam, Almir Fajkić, Bruna Perkov‐Stipičin, Rossana Roncato, Ivan Krečak, Marko Lucijanić   +7 more
wiley   +1 more source

Efficacy and safety of FLT3 inhibitors for acute myeloid leukemia: a network meta-analysis. [PDF]

Front Oncol
Xu Y, Li J, Gao Y, Huang G, Zeng Y.
europepmc   +1 more source

Cesni‐cel (ARI0002h) in ultra‐high‐risk multiple myeloma with plasma cell leukaemia or central nervous system involvement

British Journal of Haematology, Volume 209, Issue 2, Page 610-620, August 2026.
ARI0002h induced response in 15/17 patients with plasma cell leukaemia (PCL)/central nervous system (CNS)‐multiple myeloma (MM) (87% achieved ≥ very good partial response [VGPR]) with a median progression‐free survival (PFS)/overall survival (OS) of 10.5 and 15.9 months respectively.
Carlos Jimenez‐Mira, Natalia Tovar, Núria Martínez‐Cibrián, Verónica González‐Calle, Nil Albiol, Nieves López‐Muñoz, Aina Oliver‐Caldés, Azucena González, José Miguel Mateos, Marta Español‐Rego, Laura Rosiñol, Manel Juan, Paola Charry, José María Sanchez‐Pina, Sergio Navarro, Daniel Munárriz, Lucía López‐Corral, Valentín Ortiz‐Maldonado, Sara Varea, Eulalia Olesti, Julio Delgado, Álvaro Urbano‐Ispizua, Joaquín Martínez‐López, María Victoria Mateos, Luis Gerardo Rodríguez‐Lobato, Carlos Fernández de Larrea   +25 more
wiley   +1 more source

Cellular pharmacology of fludarabine: molecular determinants of transport and metabolism. [PDF]

Front Pharmacol
Mseddi M, Mlakar V, Gloor Y, Gonzales F, Baleydier F, Daali Y, Ansari M.   +6 more
europepmc   +1 more source

Central nervous system involvement and relapse in adult acute lymphoblastic leukaemia—a population‐based analysis in 2007–2022

British Journal of Haematology, Volume 209, Issue 2, Page 589-600, August 2026.
Summary Central nervous system (CNS) involvement and relapse remains a clinical challenge in the management of acute lymphoblastic leukaemia (ALL), and studies among adult ALL patients are scarce. We identified all adult ALL patients in Sweden between 2007 and 2022 (n = 838) from the population‐based ALL register and evaluated factors associated with ...
Erik Boberg, Anna Lübking, Emma Bergfelt Lennmyr, Caroline E. Dietrich, Joel Joelsson, Karin E. Smedby, Tove Wästerlid, Helene Hallböök   +7 more
wiley   +1 more source

Correspondance: Venetoclax combined with FLAG-based chemotherapy induces rapid and deep responses in early T-cell precursor lymphoblastic leukemia/lymphoma. Report of two cases and review of the literature. [PDF]

Ann Hematol
Dereme J, Segot A, Nabergoj M, Dewarrat N, Basset V, Blum S, Tsilimidos G.   +6 more
europepmc   +1 more source

Integrating ex vivo drug sensitivity and genetic mutation analysis improves prediction of chemotherapy response in acute myeloid leukemia. [PDF]

Funct Integr Genomics
Li W, Ji M, Li W, Zhou Y, Jia R, Wen X, Jin S, Hao Y, Dai M, Xu S, Zhou Q, Jiang H, Ji C, Ye J.   +13 more
europepmc   +1 more source

Corneal epithelial microcysts due to high dose Cytarabine administration in acute myeloid leukemia

Turkish Journal of Hematology, 2012
Tuba Hilkay Karapınar, Salih Gözmen, Özlem Tüfekçi, Şebnem Yılmaz, Zeynep Özbek, Melih Parlak, Gülersu İrken, Hale Ören   +7 more
doaj   +1 more source

Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia. [PDF]

Blood Lymphat Cancer
Kolosova A, Mould IA, Pepper C, Mitchell S, Pepper AGS, Ladikou EE, Simoes FA.   +6 more
europepmc   +1 more source